Parving H-H., sterby R., Anderson PW, Hsueh WADiabetic nephropathy. In: Brenner BM, editor. The Kidney. 5th ed. Philadelphia: Saunders, 1996:1864-1892.
2.
Parving H-H .Renoprotection in diabetes: genetic and non-genetic risk factors and treatment. Diabetologia1998 ; 41:745-759.
3.
Hostetter TH , Rennke HG, Brenner BMThe case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies . Am J Med1982; 72:375-380.
4.
Zatz R., Dunn BR, Meyer TW, Anderson S., Rennke HG, Brenner BMPrevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest1986 ; 77:1925-1930.
5.
Deinum J., Tarnow L., van Gool JM, et al. Plasma renin and prorenin and renin gene variation in patients with insulin-dependent diabetes mellitus and nephropathy. Nephrol Dial Transplant1999; 14:1904-1911.1 .
6.
De'Oliveira JM, Price DA, Fisher NDL, et al. Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney Int1997; 52:771-777.
7.
Wagner J., Gehlen F., Ciechanowicz A., Ritz E.Angiotensin II receptor type 1 gene expression in human glomerulonephritis and diabetes mellitus. J Am Soc Nephrol1999 ; 10:545-551.
8.
Tarnow L., Gluud C., Parving H-H.Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene. Nephrol Dial Transplant1998; 13:1125-1130.
9.
Parving H-H. , Jacobsen P., Tarnow L. et al. Effect of deletion polymorphism of angiotensin-converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin-converting enzyme: observational follow up study. Br Med J1996; 313:591-594.
10.
The Euclid Study Group.Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet1997; 349:1787-1792.
11.
Ravid M., Brosh D., Levi Z., Bar-Dayan Y., Ravid D., Rachmani R.Use of enalapril to attennuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. Ann Intern Med1998; 128:982-988.
12.
Marre M., Leblanc H., Suarez L., Guyenne T-T., Ménard J., Passa P.Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. Br Med J1987; 294:1448-1452.
13.
Mogensen CE , Keane WF, Bennett PH et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet1995; 346:1080-1084.
14.
Mathiesen ER , Hommel E., Hansen HP, Smidt UM, Parving H-H .Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria . Br Med J1999; 319:24-25.
15.
Ravid M., Savin H., Jutrin I., Bental T., Katz B., Lishner M.Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients . Ann Intern Med1993; 118:577-581. 16. Hommel E., Parving H-H., Mathiesen ER, Edsberg B., Nielsen MD, Giese J.Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. Br Med J1986; 293:466-470.
16.
Björck S., Nyberg G., Mulec H., Granerus G., Herlitz H., Aurell M.Beneficial effect of angiotensin-converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J1986; 293:471-474.
17.
Björck S., Mulec H., Johnsen SA, Nordén G., Aurell M.Renal protective effect of enalapril in diabetic nephropathy. Br Med J1992; 304:339-343.
18.
Lewis E., Hunsicker L., Bain R., Rhode R.The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy . N Engl J Med1993; 329:1456-1462. 20. Andersen S., Tarnow L., Rossing P., Hansen BV, Parving H-H.Renoprotective effects of angiotensin II receptor blokade in type 1 diabetic patients with diabetic nephropathy. Kidney Int2000; In press.
